Catalyst Pharmaceuticals
Jennifer Isler OCain, PhD has an extensive work experience in the pharmaceutical industry. Jennifer started their career at Wyeth in 2005 as Laboratory Head, Genomic Biomarkers, where they worked until 2008. Jennifer then joined Boehringer Ingelheim as Head, Biotherapeutic Bioanalysis and worked there until 2014. After that, Jennifer joined Pfizer and held various roles including Director, Competitive Intelligence from 2014 to 2019, and Director, Strategy & Consulting from 2019 to 2020. Currently, they are working as the Executive Director, Portfolio Strategy & Alliance Management at Catalyst Pharmaceuticals, Inc. from 2022 onwards.
Jennifer Isler OCain, PhD obtained their Doctor of Philosophy degree in Cell/Cellular and Molecular Biology from the University of Pennsylvania, where they studied from 1996 to 2001.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.